X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9940) 9940
Publication (925) 925
Book Chapter (125) 125
Book Review (88) 88
Conference Proceeding (37) 37
Magazine Article (9) 9
Dissertation (8) 8
Paper (6) 6
Book / eBook (5) 5
Web Resource (5) 5
Data Set (3) 3
Government Document (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6195) 6195
index medicus (4512) 4512
animals (3795) 3795
male (2938) 2938
female (2285) 2285
diabetes mellitus, type 2 - drug therapy (2239) 2239
dipeptidyl peptidase 4 - metabolism (1781) 1781
dipeptidyl-peptidase iv inhibitors - therapeutic use (1767) 1767
middle aged (1463) 1463
endocrinology & metabolism (1435) 1435
type 2 diabetes (1407) 1407
rats (1406) 1406
hypoglycemic agents - therapeutic use (1360) 1360
biochemistry & molecular biology (1359) 1359
mice (1308) 1308
diabetes (1215) 1215
glucagon-like peptide-1 (1214) 1214
pharmacology & pharmacy (1102) 1102
adult (1095) 1095
aged (1092) 1092
dipeptidyl-peptidase iv inhibitors - pharmacology (990) 990
dipeptidyl peptidase 4 (944) 944
dipeptidyl peptidase-iv (901) 901
dipeptidyl-peptidases and tripeptidyl-peptidases - metabolism (883) 883
expression (849) 849
dipeptidyl peptidase iv (836) 836
sitagliptin (815) 815
analysis (784) 784
glucose (744) 744
dipeptidyl-peptidase iv inhibitors - adverse effects (731) 731
treatment outcome (696) 696
dipeptidyl-peptidase-iv (687) 687
adamantane - analogs & derivatives (664) 664
diabetes mellitus, type 2 - blood (664) 664
amino acid sequence (655) 655
research (655) 655
molecular sequence data (644) 644
cell biology (639) 639
cd26 (635) 635
immunology (629) 629
insulin (590) 590
blood glucose - metabolism (589) 589
metformin (581) 581
diabetes mellitus (567) 567
hypoglycemic agents - adverse effects (559) 559
hypoglycemic agents (554) 554
dipeptidyl-peptidase iv inhibitors - administration & dosage (544) 544
double-blind (541) 541
glycemic control (541) 541
dipeptidyl peptidase-4 inhibitor (533) 533
hypoglycemic agents - pharmacology (527) 527
care and treatment (525) 525
peptides (511) 511
sitagliptin phosphate (509) 509
proteins (508) 508
drug therapy, combination (507) 507
peptidase (505) 505
dipeptidyl peptidase 4 - genetics (501) 501
enzymes (493) 493
vildagliptin (489) 489
blood glucose - drug effects (484) 484
risk factors (451) 451
chemistry, medicinal (449) 449
hypoglycemic agents - administration & dosage (446) 446
medicine, research & experimental (440) 440
proteases (438) 438
kinetics (436) 436
glp-1 (426) 426
dipeptidyl peptidase 4 - blood (415) 415
type 2 diabetes mellitus (411) 411
physiological aspects (408) 408
inhibitors (407) 407
type-2 diabetes-mellitus (403) 403
substrate specificity (394) 394
dipeptidyl-peptidase iv inhibitors (392) 392
internal medicine (390) 390
cells, cultured (385) 385
safety (384) 384
health aspects (383) 383
metformin - therapeutic use (383) 383
dipeptidyl peptidase 4 - chemistry (379) 379
mice, inbred c57bl (378) 378
glucagon (376) 376
dipeptidyl-peptidases and tripeptidyl-peptidases - genetics (369) 369
medicine, general & internal (368) 368
dextrose (367) 367
diabetes mellitus, type 2 - metabolism (367) 367
adamantane - therapeutic use (366) 366
time factors (366) 366
activation (365) 365
drug therapy (364) 364
diabetes mellitus, type 2 - complications (363) 363
inflammation (362) 362
abridged index medicus (355) 355
article (351) 351
efficacy (351) 351
structure-activity relationship (347) 347
cell line (345) 345
beta-cell function (344) 344
cells (344) 344
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9761) 9761
Japanese (102) 102
German (62) 62
French (40) 40
Russian (38) 38
Korean (34) 34
Spanish (32) 32
Czech (27) 27
Chinese (20) 20
Hungarian (15) 15
Polish (15) 15
Italian (8) 8
Dutch (6) 6
Croatian (5) 5
Danish (4) 4
Norwegian (3) 3
Portuguese (3) 3
Swedish (3) 3
Ukrainian (2) 2
Serbian (1) 1
Slovak (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Periodontology, ISSN 0303-6979, 06/2018, Volume 45, Issue S19, pp. 379 - 379
Journal Article
Archives of Oral Biology, ISSN 0003-9969, 06/2019, Volume 102, pp. 238 - 243
Objective: To investigate the effects of sitagliptin, a dipeptidyl peptidase 4 inhibitor used to treat type II diabetes, on bone tissue and on implant... 
Incretins | Dipeptidyl peptidase 4 | Implants
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 12/2009, Volume 11, Issue 12, pp. 1145 - 1152
Aims: To assess the efficacy and safety of alogliptin added to insulin in patients with type 2 diabetes inadequately controlled with insulin alone or combined... 
dipeptidyl peptidase 4 inhibitor | insulin type 2 diabetes | alogliptin | Dipeptidyl peptidase 4 inhibitor | Alogliptin | Insulin type 2 diabetes
Journal Article
Clinica Terapeutica, ISSN 0009-9074, 2018, Volume 169, Issue 2, pp. e60 - e61
Journal Article
NATURE REVIEWS CANCER, ISSN 1474-175X, 10/2007, Volume 7, Issue 10, pp. 800 - 808
Proteases have long been associated with cancer progression because of their ability to degrade extracellular matrices, which facilitates invasion and... 
CELL LUNG-CANCER | MATRIX METALLOPROTEINASES | PROMOTER HYPERMETHYLATION | ONCOLOGY | HUMAN MACROPHAGE METALLOELASTASE | PROSTATE-SPECIFIC ANTIGEN | GENE-EXPRESSION | SERINE-PROTEASE | HUMAN BREAST-CANCER | NF-KAPPA-B | DIPEPTIDYL PEPTIDASE-IV
Journal Article
The FASEB Journal, ISSN 0892-6638, 01/2020, Volume 34, Issue 1, pp. 807 - 821
Kv4 pore‐forming subunits co‐assemble with β‐subunits including KChIP2 and DPP6 and the resultant complexes conduct cardiac transient outward K+ current (Ito).... 
K+ channel‐interacting protein | dipeptidyl peptidase‐like protein | transient outward K+ current | cardiomyocyte
Journal Article
JOURNAL OF MEDICINAL CHEMISTRY, ISSN 0022-2623, 09/2019, Volume 62, Issue 17, pp. 7874 - 7884
Over the past decade, there has been increasing interest in covalent inhibition as a drug design strategy. Our own interest in the development of prolyl... 
TARGET | DESIGN | MUTAGENESIS | CHEMISTRY, MEDICINAL | SERINE | CYSTEINE | SELECTIVITY | DISCOVERY | DIPEPTIDYL PEPTIDASE-IV | PREDICTION
Journal Article
Chemical Science, ISSN 2041-6520, 07/2010, Volume 1, Issue 1, pp. 13 - 31
The utility of copper-mediated cross-coupling reactions has been significantly increased by the development of mild reaction conditions and the ability to... 
NITROGEN-CONTAINING HETEROCYCLES | CROSS-COUPLING REACTIONS | ULLMANN-TYPE SYNTHESIS | AMINO-ACID | SULFINIC ACID SALTS | DIPEPTIDYL-PEPTIDASE-IV | C-N | ARYL HALIDES | N BOND FORMATION | HIGHLY EFFICIENT SYNTHESIS | CHEMISTRY, MULTIDISCIPLINARY
Journal Article
by Hou, WJ and Sun, H and Ma, YF and Liu, CY and Zhang, ZY
JOURNAL OF MEDICINAL CHEMISTRY, ISSN 0022-2623, 06/2019, Volume 62, Issue 12, pp. 5901 - 5919
In the course of developing the biochemistry to chemistry activity-based protein profiling (BTC-ABPP) method, we herein unexpectedly discovered that the... 
ACTIVATION | DESIGN | CHEMISTRY, MEDICINAL | SERINE PROTEASES | DIPEPTIDYL PEPTIDASE-I | REQUIRES | GENERATION | DISCOVERY
Journal Article
KIDNEY INTERNATIONAL, ISSN 0085-2538, 09/2015, Volume 88, Issue 3, pp. 479 - 489
Integrin beta 1 and dipeptidyl peptidase (DPP)-4 play roles in endothelial cell biology. Vascular endothelial growth factor (VEGF)-A inhibits... 
CELLS | Flt1 | BETA-1-INTEGRIN | DIPEPTIDYL-PEPTIDASE-IV | Flk1 | smad3 | RENAL FIBROSIS | GROWTH-FACTOR-BETA | KIDNEY FIBROSIS | CD29 | MOUSE MODEL | UROLOGY & NEPHROLOGY | CD26 | MICE | STREPTOZOTOCIN | DIABETIC GLOMERULOPATHY | EndMT
Journal Article
10/2011
Sitagliptin is a newer oral hypoglycemic drug of the dipeptidyl peptidase-IV inhibitor class. It appears to be a promising newer oral hypoglycemic agent. The... 
sitagliptin | Dipeptidyl peptidase inhibitor | hemolysis
Web Resource
The New England Journal of Medicine, ISSN 0028-4793, 10/2013, Volume 369, Issue 14, pp. 1327 - 1335
Alogliptin, a new antihyperglycemic agent of the DPP-4 class, was shown to have no significant effect on cardiovascular risk over a median treatment period of... 
INHIBITOR ALOGLIPTIN | MEDICINE, GENERAL & INTERNAL | CARDIOVASCULAR SAFETY | MELLITUS | OUTCOMES | MYOCARDIAL-INFARCTION | Hypoglycemic Agents - therapeutic use | Double-Blind Method | Dipeptidyl-Peptidase IV Inhibitors - adverse effects | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Uracil - therapeutic use | Male | Myocardial Infarction - complications | Myocardial Infarction - drug therapy | Uracil - adverse effects | Angina, Unstable - drug therapy | Piperidines - therapeutic use | Angina, Unstable - complications | Piperidines - adverse effects | Cardiovascular Diseases - mortality | Female | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Uracil - analogs & derivatives | Type 2 diabetes | Care and treatment | Acute coronary syndrome | Patient outcomes | Risk factors | Myocardial infarction | Heart attacks | Cardiovascular disease | Angina | Drug development | Hemoglobin | Diabetes mellitus (non-insulin dependent) | Drug dosages | Cerebral infarction | Stroke | Peptidase | Statistical analysis | Diabetes mellitus | Pancreatitis | Committees | FDA approval | Hypoglycemia | Angina pectoris | Studies | Product development | Diabetes | Acute coronary syndromes | Cardiovascular diseases | Health risk assessment | Cancer
Journal Article